Current through Register Vol. 49, No. 9, September, 2024
I.
AUTHORITY
This rule is issued pursuant to Ark. Code Ann. §
23-92-606
which mandates that the Insurance Commissioner ("Commissioner") shall
promulgate a rule to implement the subchapter pertaining to the 340B Drug
Pricing Nondiscrimation Act.
II.
DEFINITIONS
As used in this Rule:
(1) "Arkansas-based community pharmacy" means
a Pharmacy licensed and located in this State;
(2) "Covered entity" means an entity that
meets the 340B Drug Pricing Program's eligibility requirements found at
42
U.S.C. §
256b(a)(4) and
is enrolled in the 340B Drug Pricing Program;
(3) "Patient" means an individual who has an
established relationship with a covered entity and is seeking medical diagnosis
and treatment from the covered entity;
(4) "Pharmacy" means the same as defined in
§
17-92-101;
(5) "Provider" means a licensed pharmacist as
defined in §
17-92-101;
(6)
(A)
"Third party" means:
(i) A payor or the
payor's intermediary; or
(ii) A
pharmacy benefits manager.
(B) "Third party" does not include:
(i) The Arkansas Medicaid Program;
(ii) A risk-based provider organization as
established under the Medicaid Provider-Led Organized Care Act, §
20-77-2701 et
seq.; or
(iii) A self-insured
governmental plan or a pharmacy benefits manager for a self-insured
governmental plan; and
(7) "340B drug pricing" means the acquisition
and delivery of 340B-priced drugs as established under section 602 of the
Veterans Health Care Act of 1992,
Pub.
L. No. 102-585.
III.
THIRD PARTY REQUIREMENTS
A third party shall:
(1) Inform a patient that the patient is not
required to use a mail-order pharmacy;
(2) Obtain a signed waiver from a patient
before allowing the use of a mail-order pharmacy;
(3) Make drug formulary and coverage
decisions based on the third party's normal course of business;
(4) Allow a patient the freedom to use any
pharmacy or any provider the patient chooses, whether or not the pharmacy
participates in 340B drug pricing; and
(5) Eliminate discriminatory contracting as
it relates to:
(A) Transferring the benefit of
340B drug-pricing savings from one (1) entity, including critical access
hospitals, federally qualified health centers, other hospitals, or 340B
drug-pricing participants and their underserved patients, to another entity,
including without limitation pharmacy benefits managers, private insurers, and
managed care organizations;
(B)
Pricing that occurs when offering a lower reimbursement for a drug purchased
under 340B drug pricing than for the same drug not purchased under 340B drug
pricing;
(C) Refusal to cover drugs
purchased under 340B drug pricing;
(D) Refusal to allow 340B drug-pricing
pharmacies to participate in networks; and
(E) Charging more than fair market value or
seeking profit sharing in exchange for services involving 340B drug
pricing.
IV.
THIRD PARTY AND PHARMACEUTICAL MANUFACTURER PROHIBITIONS
(a) A third party shall not:
(1) Coerce a patient into using a mail-order
pharmacy;
(2) Require a patient to
use a mail-order pharmacy;
(3)
Discriminate, lower the reimbursement, or impose any separate terms upon a
pharmacy in any other third party contract on the basis that a pharmacy
participates in 340B drug pricing;
(4) Require a pharmacy to reverse, resubmit,
or clarify a 340B drug-pricing claim after the initial adjudication unless
these actions are in the normal course of pharmacy business and not related to
340B drug pricing;
(5) Require a
billing modifier to indicate that the drug or claim is a 340B drug-pricing
claim unless the drug or claim is being billed to the fee-for-service Arkansas
Medicaid Program;
(6) Modify a
patient's copayment on the basis of a pharmacy's participation in 340B drug
pricing;
(7) Exclude a pharmacy
from a network on the basis of the pharmacy's participation in 340B drug
pricing;
(8) Establish or set
network adequacy requirements based on 340B drug pricing participation by a
provider or a pharmacy; or
(9)
Prohibit an entity authorized to participate in 340B drug pricing or a pharmacy
under contract with an entity authorized to participate in 340B drug pricing
from participating in the third party's provider network on the basis of
participation in 340B drug pricing.
(b) A third party that is a pharmacy benefits
manager shall not base the drug formulary or drug coverage decisions upon the
340B drug-pricing status of a drug, including price or availability, or whether
a dispensing pharmacy participates in 340B drug pricing.
(c) A pharmaceutical manufacturer shall not;
(1) Prohibit a pharmacy from contracting or
participating with an entity authorized to participate in 340B drug pricing by
denying access to drugs that are manufactured by the pharmaceutical
manufacturer; or
(2) Deny or
prohibit 340B drug pricing for an Arkansas-based community pharmacy that
receives drugs purchased under a 340B drug pricing contract pharmacy
arrangement with an entity authorized to participate in 340B drug
pricing.
V.
PHARMACY CLAIMS
All pharmacy claims processed by a pharmacy that participates
in 340B drug pricing are final at the point of adjudication.
VI.
PENALTIES
The penalties, actions or orders, as authorized under Ark. Code
Ann. §§
23-66-209
and
23-66-210,
shall apply to violations of this Rule.
VII.
EFFECTIVE DATE
This Rule is effective after review and approval by the
Arkansas Legislative Council, ten (10) days after filing of the approved Rule
with the Arkansas Secretary of State.